Left to proper: Olivia Ferro and Chloe Ferro, co-founders of SheMed (Credit score: SheMed)
Feminine-founded HealthTech agency SheMed has reached unicorn standing after a $50 million (£37.3m) Collection A funding spherical, taking its valuation to $1bn (£750m).
The UK-based startup gives a weight-management service for girls utilizing GLP-1 remedy alongside a digital platform which offers medical recommendation, information insights and assist.
The brand new funding will probably be used to broaden the agency’s UK operations, scaling its medical and expertise groups, strengthening medical infrastructure and enhancing its data-driven capabilities.
Olivia Ferro, co-founder and chief govt at SheMed, advised Digital Well being Information: “Attaining unicorn standing validates the size of the unmet wants for world class GLP-1 care.
“It exhibits that personalisation shouldn’t be a luxurious however an expectation of a brand new era of ladies who need care that’s data-led, clinically exact, and constructed round their particular person well being journey.”
The funding may even assist new analysis and patient-experience initiatives designed to enhance entry to personalised care for girls within the UK.
SheMed’s programme integrates medical oversight, wellness monitoring and assist by way of an all-in-one digital platform for girls.
Ferro added: “For greater than a decade, I looked for solutions to an undiagnosed well being difficulty.
“As a GLP-1 affected person myself, I understand how transformative the appropriate prognosis and remedy may be.
“We constructed SheMed to provide ladies the personalised assist I struggled to search out: care that listens, understands and empowers.”
SheMed was based in April 2024 by sisters Olivia and Chloe Ferro and since then has cared for greater than 60,000 members.
In August, SheMed partnered with MedTech agency Tasso to combine a blood check into its choices.
Chloe Ferro, co-founder and president of SheMed, stated: “The demand for SheMed’s companies has been extraordinary.
“Girls are searching for care that recognises their individuality, their biology and their experiences.
“It’s why ladies proceed to show to SheMed for a tailor-made, extra supportive path to healthcare.”
Later this month, SheMed will publish outcomes from the first-ever female-focused GLP-1 medical examine, marking a big milestone in ladies’s metabolic-health analysis.
The findings will present insights into how GLP-1 drugs have an effect on ladies’s hormonal and metabolic responses, serving to refine future remedy pathways.
SheMed shouldn’t be disclosing investor data for the Collection A spherical.
It’s the second UK-based femtech agency to achieve a $1bn valuation, following ladies’s well being app Flo Well being’s announcement in July 2024 that it had reached unicorn standing after elevating greater than $200m in Collection C funding.
In the meantime, the NHS is coping with a rise in demand for GLP-1 remedy, used to deal with diabetes kind 2 and weight problems, following the Nationwide Institute for Care Excellence suggestion of Tirzepatide for adults with a BMI over 35 and at the least one weight-related long-term well being situation, printed in December 2024.
In January 2025, digital well being agency Inhealthcare launched a self-referral service to assist NHS organisations handle the anticipated surge in demand for brand spanking new weight reduction drugs.
